乙基 1H-吡咯-3-羧酸 | 37964-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 乙基 1H-吡咯-3-羧酸
• 中文别名: 乙基1H-吡咯-3-羧酸；1H-吡咯-3-羧酸乙酯
• 英文名称: Ethyl 1H-pyrrole-3-carboxylate
• 英文别名: pyrrole-3-carboxylic acid ethyl ester
• CAS: 37964-17-3
• 化学式: C₇H₉NO₂
• mdl: MFCD10000696
• 分子量: 139.154
• InChiKey: ICJYWDHNTMJKFP-UHFFFAOYSA-N

物化性质

• 熔点：
  118℃
• 沸点：
  291.8±13.0℃ (760 Torr)
• 密度：
  1.139±0.06 g/cm3 (20℃ 760 Torr)
• 闪点：
  130.3±19.8℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  乙基 1H-吡咯-3-羧酸 在 manganese(IV) oxide 、 二异丁基氢化铝 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 0.5h， 生成 吡咯-3-甲醛
  参考文献：
  名称：

  Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors

  摘要：

  Glycolysis is drastically increased in tumors and it is the main route to energy production with a minor use of oxidative phosphorylation. Among the key enzymes in the glycolytic process, LDH is emerging as one of the most interesting targets for the development of new inhibitors. In this context, in the present work, we carried out a virtual screening procedure followed by chemical modifications of the identified structures according to a "hit-to-lead" process. The effects of the new molecules were preliminary probed against purified human LDH-A. The compounds active at low micromolar level were additionally characterized for their activity on some cellular metabolic processes by using Raji human cell line. Within the series, 1 was considered the best candidate, and a more detailed characterization of its biological properties was performed. In Raji cells exposed to compound 1 we evidenced the occurrence of effects usually observed in cancer cells after LDH-A inhibition: reduced lactate production and NAD/NADH ratio, apoptosis. The flow cytometry analysis of treated cells also showed cell cycle changes compatible with effects exerted at the glycolytic level. Finally, in agreement with the data obtained with other inhibitors or by silencing LDH-A expression, compound 1 was found to increase Rail cells response to some commonly used chemotherapeutic agents. Taken together, all these finding are in support of the LDH-A inhibiting activity of compound 1. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.06.028
• 作为产物：
  描述：

  草酰乙酸二乙酯 在 喹啉 、 氢氧化钾 、 copper oxide-chromium oxide 作用下， 生成 乙基 1H-吡咯-3-羧酸
  参考文献：
  名称：

  Rinkes, Recueil des Travaux Chimiques des Pays-Bas, 1937, vol. 56, p. 1228

  摘要：

  DOI：

文献信息

• Nuclear Hormone Receptor Modulators
  申请人：Cusack Kevin P.

  公开号：US20120238549A1

  公开（公告）日：2012-09-20

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了一种公式(I)的化合物，其中变量如本文所述定义。所述化合物的药用盐、前药、生物活性代谢物、立体异构体和同分异构体。本发明的化合物可用于治疗免疫学和肿瘤学疾病。
• [EN] Pyrazolopyrrolidine compounds<br/>[FR] COMPOSÉS PYRAZOLOPYRROLIDINE
  申请人：NOVARTIS AG

  公开号：WO2013080141A1

  公开（公告）日：2013-06-06

  The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

  该发明涉及公式（I）所述的化合物，包括这些化合物的药物制剂，以及这些化合物在治疗由MDM2和/或MDM4活性介导的疾病或疾病中的用途和使用方法，以及包含这些化合物的组合物。
• Northern–Southern Route to Synthetic Bacteriochlorins
  作者：Yizhou Liu、Jonathan S. Lindsey

  DOI：10.1021/acs.joc.6b02334

  日期：2016.12.2

  was prepared in five steps from an α-halopyrrole and a 2,2-dimethylpent-4-ynoic acid. The first three steps follow Jacobi’s synthesis of dihydrodipyrrins: Pd-mediated coupling to form a lactone–pyrrole, Petasis reagent treatment for methenylation, and Paal–Knorr type ring closure to form the 1,2,2-trimethyl-substituted dihydrodipyrrin. Subsequent steps entail conversion of the 1-methyl group to the

  通过二氢联吡啶-乙醛的北-南（NS）自缩合获得细菌绿素的新途径补充了先前的东-西（EW）途径。从α-卤代吡咯和2，2-二甲基戊-4-炔酸分五个步骤制备每种细菌绿素。前三个步骤遵循Jacobi合成的二氢联吡啶类化合物：Pd介导的偶联形成内酯-吡咯，Petasis试剂进行亚甲基化处理，Paal-Knorr型闭环形成1,2,2-三甲基取代的二氢联吡啶。随后的步骤需要将1-甲基转化为1-（二甲氧基甲基）单元，并通过酸催化的自缩合反应生成二氢联吡啶-乙缩醛。NS和EW路线之间的本质区别在于（1）宝石的位置-二甲基（相对于1-缩醛单元而言）分别位于二氢双吡啶-缩醛的2-和3-位，（2）二氢联吡啶的合成方法，因此（3）获得各种取代的细菌绿素包括那些在中位具有取代基的基团。制备了十个在β-吡咯和/或内消旋位置带有0-6个总芳基，烷基和碳乙氧基取代基的新细菌素，大环形成的产率高达39％。确定了四个单晶X射线
• PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150031673A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): wherein A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , R 5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物： 其中A 1 ，A 2 ，R a ，R b ，R c ，R d ，R 3 ，R 4 ，R 5 和T的定义如描述中所述。 含有这些化合物的药物产品对于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病，具有益处。
• Heterocyclic compounds as ligands of the GABAA receptor
  申请人：——

  公开号：US20030105081A1

  公开（公告）日：2003-06-05

  Disclosed are heterocyclic compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein the variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n and m are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptor.

  揭示了具有以下公式的杂环化合物及其药用可接受的盐，其中变量A、V、Y、J、E、X、T、G、Q、W、Z、b、n和m在此处被定义。这些化合物是GABA A 脑受体的高度选择性激动剂、拮抗剂或逆激动剂，或者是GABA A 脑受体的激动剂、拮抗剂或逆激动剂的前药。